Skip to main content
. 2022 Aug 11;28(11):1546–1551. doi: 10.1016/j.jiac.2022.08.007

Table 1.

Characteristics of the participants in the Omicron and control groups before propensity score matching.

Characteristics Omicron group
Control group
SMD p-valuea
(n = 53) (n = 502)
Age (years), median (IQR) 56.0 (35.0, 69.5) 48.0 (42.0, 55.0) 0.011
Older adultb, No. (%) 17 (32.1)c 24 (4.8) 0.767 <0.001
Female sex, No. (%) 14 (26.4) 300 (59.8) 0.714 <0.001
BMId, median (IQR) 24.4 (22.2, 26.8) 23.1 (20.7, 25.9) 0.045
Obesitye, No. (%) 23 (43.4) 150 (30.0) 0.281 0.045
Ethnicity, No. (%)
 Japanese 44 (83.0) 502 (100)
 Asian 4 (7.5) 0 (0.0)
 Caribbean 3 (5.7) 0 (0.0)
 African 2 (3.8) 0 (0.0)
Smoking history, No. (%)
 Yes 25 (47.2) 206 (41.0) 0.225
Individual comorbidities, No. (%)
 No medical conditions 27 (50.9) 234 (46.6) 0.885
 Hypertension 10 (18.9) 70 (13.9) 0.450
 Dyslipidemia 10 (18.9) 59 (11.8) 0.200
 Diabetes 4 (7.5) 19 (3.8) 0.277
 COPD 1 (1.9) 2 (0.4) 0.275
 Bronchial asthma 3 (5.7) 69 (13.7) 0.700
 Myocardial infarction 1 (1.9) 0 (0.0) 0.102
 Malignancy 8 (15.1) 11 (2.2) <0.001
 Immunodeficiency 1 (1.9) 2 (0.4) 0.275
 Chronic kidney disease 2 (3.8) 2 (0.4) 0.053
Vaccinationf, No. (%) 45 (84.9) 11 (2.2) 2.994 <0.001
Acute COVID-19 characteristics, No. (%)
 Pneumonia diagnosed 12 (22.6) 141 (28.1) 0.214
 Severityg 0.173
 Mild 42 (79.2) 393 (78.3)
 Moderate 11 (20.8) 58 (12.7)
 Severe 0 (0.0) 4 (0.9)
Pharmacological treatments
 Antiviral 13 (24.5) 56 (11.2) 0.020
 Corticosteroids 12 (22.6) 58 (11.6) 0.067
 mAbh 13 (24.5) 4 (0.8) <0.001

Abbreviations: SMD, standardized mean difference; BMI, body mass index; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; IMV, invasive mechanical ventilation.

a

Mann–Whitney U test for continuous variables, Fisher's exact test or Kruskal−Wallis test for categorical variables.

b

Older adult is defined as aged 65 or more.

c

The denominator in each category depends on the number of missing values.

d

Calculated as weight in kilograms divided by height in meters squared.

e

Obesity is defined as BMI of 25 or more.

f

Patients tested positive for SARS-CoV-2 at least 7 days after their second vaccination when immunity had developed.

g

Highest severity during clinical course of COVID-19.

h

Monoclonal antibodies were either casirivimab/imdevimab or sotrovimab.